Key result
Bradykinin stimulates endothelial tPA release via a B2 receptor-dependent, NO-independent mechanism.
Why the study?
The mechanisms underlying bradykinin-stimulated tissue plasminogen activator release from human endothelium were unknown.
Does bradykinin stimulate tPA release through B2 receptor, NO synthase, or cyclooxygenase pathways in healthy volunteers?
Does bradykinin stimulate tPA release through B2 receptor, NO synthase, or cyclooxygenase pathways in healthy volunteers?
Bradykinin stimulates tPA release from human endothelium through a B2 receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway.
Answers are grounded in this paper and cite their sources.
No immediate clinical implications for antithrombotic therapy; leaves open bradykinin’s role in pathologic thrombosis.
BACKGROUND: Bradykinin stimulates dose-dependent tissue plasminogen activator (tPA) release from human endothelium. Although bradykinin is known to cause vasodilation through B(2) receptor-dependent effects on NO, prostacyclin, and endothelium-derived hyperpolarizing factor production, the mechanism(s) underlying tPA release is unknown. METHODS AND RESULTS: We measured the effects of intra-arterial bradykinin (100, 200, and 400 ng/min), acetylcholine (15, 30, and 60 microg/min), and nitroprusside (0.8, 1.6, and 3.2 microg/min) on forearm vasodilation and tPA release in healthy volunteers in the presence and absence of (1) the B(2) receptor antagonist HOE 140 (100 microg/kg IV), (2) the NO synthase inhibitor L-N:(G)-monomethyl-L-arginine (L-NMMA, 4 micromol/min intra-arterially), and (3) the cyclooxygenase inhibitor indomethacin (50 mg PO TID). B(2) receptor antagonism attenuated vasodilator (P:=0.004) and tPA (P:=0.043) responses to bradykinin, without attenuating the vasodilator response to nitroprusside (P:=0.36). L-NMMA decreased basal forearm blood flow (from 2.35+/-0.31 to 1. 73+/-0.22 mL/min per 100 mL, P:=0.01) and blunted the vasodilator response to acetylcholine (P:=0.013) and bradykinin (P:=0.07, P:=0. 038 for forearm vascular resistance) but not that to nitroprusside (P:=0.47). However, there was no effect of L-NMMA on basal (P:=0.7) or bradykinin-stimulated tPA release (P:=0.45). Indomethacin decreased urinary excretion of the prostacyclin metabolite 2, 3-dinor-6-keto-prostaglandin F(1alpha) (P:=0.04). The vasodilator response to endothelium-dependent (P:=0.019 for bradykinin) and endothelium-independent (P:=0.019) vasodilators was enhanced during indomethacin administration. In contrast, there was no effect of indomethacin alone (P:=0.99) or indomethacin plus L-NMMA (P:=0.36) on bradykinin-stimulated tPA release. CONCLUSIONS: These data indicate that bradykinin stimulates tPA release from human endothelium through a B(2) receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway. Bradykinin-stimulated tPA release may represent a marker for the endothelial effects of endothelium-derived hyperpolarizing factor.
No takes yet. Share an insight, caveat, or question.
Brown et al. (2000) studied Healthy volunteers. Bradykinin vs. Absence of inhibitors (HOE 140, L-NMMA, indomethacin) was evaluated on Forearm vasodilation and tissue plasminogen activator (tPA) release (p=0.043). Bradykinin stimulates tissue plasminogen activator release from human endothelium through a B2 receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway.
Synapse has enriched 10 related papers. Consider them for comparative context: